China will add more drugs to its centralised procurement program as the country looks to curtail high drug prices, as reported by This is Money.
According to a meeting chaired by Premier Li Keqiang, generic versions will be prioritised for inclusion in the bulk-buying program.
Drugs on the list so far include off-patent cancer treatment pemetrexed, marketed by Eli Lilly under the name Alimta, as well as the leukemia drug imatinib, which is sold by Novartis as Gleevec.
The move has caused the price of some medicines to drop more than 90%, according to the news source.
To read more NewsPoints articles, click here.